Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2Completed 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1CNS 1

Conditions

Glioma 3Leukemia, Myeloid, Acute 2Cholangiocarcinoma 2Recurrence 1Neoplasms, Unknown Primary 1IDH1 Mutation Myeloid Neoplasms 1Chondrosarcoma 1

Interventions

Gemcitabine 39Cisplatin 24Oxaliplatin 15pembrolizumab 12Capecitabine 12Fluorouracil 9Leucovorin 7Albumin-Bound Paclitaxel 7lenvatinib 6Radiofrequency Ablation 6Panitumumab 6130-nm albumin-bound paclitaxel 6Irinotecan 5Bevacizumab 5durvalumab 4Taxes 4Nivolumab 4Hepatectomy 4Drug Therapy 4tremelimumab 3apatinib 3Radiosurgery 3Platinum 3Injections 3Floxuridine 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3trametinib 2spartalizumab 2sintilimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Cholangiocarcinoma × ivosidenib × Clear all
NCT02073994 2026-02-17

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Servier

Phase 1 Completed
174 enrolled
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

NCT02989857 2024-08-20

ClarIDHy

Servier

Phase 3 Completed
187 enrolled 34 charts 1 FDA
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡